Randomised, Double-Blind, Placebo-Controlled Study to Investigate GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years

Trial Profile

Randomised, Double-Blind, Placebo-Controlled Study to Investigate GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2018

At a glance

  • Drugs GNbAC1 (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms RAINBOW-T1D
  • Sponsors GeNeuro Australia
  • Most Recent Events

    • 26 Jul 2018 According to a GeNeuro media release, The preliminary results at 6 months of this study are expected by the end of September 2018.
    • 09 Jan 2018 According to a GeNeuro media release, the company anticipates to share data from the trial during the third quarter 2018.
    • 09 Jan 2018 Status changed from recruiting to active, no longer recruiting, according to a GeNeuro media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top